• Lead investors Varian and OrbiMed, are joined by Perceptive Advisors, Pivotal bioVenture Partners, Rock Springs Capital and all existing investors • Funding to Accelerate the Development of Targeted Alpha Therapeutics Across Multiple Cancer Types Based on Fusion’s Fast-Clear™ Linker Technology Platform BOSTON & HAMILTON, Ontario, April 2, 2019-- Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed.